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Abstract
Background: Gliomas in dogs remain poorly understood.
Objectives: To characterize the clinicopathologic findings, diagnostic imaging fea-
tures and survival of a large sample of dogs with glioma using the Comparative Brain
Tumor Consortium diagnostic classification.
Animals: Ninety-one dogs with histopathological diagnosis of glioma.
Methods: Multicentric retrospective case series. Signalment, clinicopathologic find-
ings, diagnostic imaging characteristics, treatment, and outcome were used. Tumors
were reclassified according to the new canine glioma diagnostic scheme.
Results: No associations were found between clinicopathologic findings or survival and
tumor type or grade. However, definitive treatments provided significantly (P = .03)
improved median survival time (84 days; 95% confidence interval [CI], 45-190)
Abbreviations: CBTC, Comparative Brain Tumor Consortium; CE, contrast enhancement; CI, confidence interval; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computed
tomography; FLAIR, fluid-attenuation inversion recovery; GFAP, glial fibrillary acidic protein; GRE, gradient-recalled echo; HA, high-grade astrocytoma; HO, high-grade oligodendroglioma; HU,
high-grade undefined glioma; LA, low-grade astrocytoma; LO, low-grade oligodendroglioma; MRI, magnetic resonance imaging; MST, median survival time; OR, odds ratio; WHO, World Health
Organization.
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compared to palliative treatment (26 days; 95% CI, 11-54). On magnetic resonance imag-
ing (MRI), oligodendrogliomas were associated with smooth margins and T1-weighted
hypointensity compared to astrocytomas (odds ratio [OR], 42.5; 95% CI, 2.42-744.97;
P = .04; OR, 45.5; 95% CI, 5.78-333.33; P < .001, respectively) and undefined gliomas
(OR, 84; 95% CI, 3.43-999.99; P = .02; OR, 32.3; 95% CI, 2.51-500.00; P = .008, respec-
tively) and were more commonly in contact with the ventricles than astrocytomas (OR,
7.47; 95% CI, 1.03-53.95; P = .049). Tumor spread to neighboring brain structures was
associated with high-grade glioma (OR, 6.02; 95% CI, 1.06-34.48; P = .04).
Conclusions and Clinical Importance: Dogs with gliomas have poor outcomes, but
risk factors identified in survival analysis inform prognosis and the newly identified
MRI characteristics could refine diagnosis of tumor type and grade.
K E YWORD S
astrocytoma, dog, magnetic resonance imaging, oligodendroglioma, prognosis, tumor grade,
undefined glioma
1 | INTRODUCTION
The incidence of brain tumors in adult dogs is 2.8% to 4.5% and,
although individual studies vary, gliomas represent 36% to 70% of pri-
mary brain tumors in dogs.1-5 Consequently, glioma in dogs is increas-
ingly recognized as a naturally occurring model for understanding
human glioma. The benefits include the size and structure of the
canine brain, the incidence of spontaneous gliomas, and the coexis-
tence with an active immune system.6,7 Nevertheless, there are many
gaps in knowledge related to the natural biology of glioma in dogs as
well as its molecular characteristics.
Epidemiologic data on glioma in dogs indicates a median age at
diagnosis of 8 years, a male predilection (incidence ratio of 1.53 for
males/females), and predominant lesion location within the fronto-
olfactory, temporal, and parietal lobes of the brain.3,5,8 Over 50% of
all gliomas in dogs occur in certain brachycephalic breeds3,5,8-10 and
the Boston Terrier, Bulldog, and Boxer breeds have a higher preva-
lence of oligodendroglioma.8 On magnetic resonance imaging (MRI),
intracranial gliomas in dogs are typically described as intra-axial,
T1-weighted iso- to hypointense and T2-weighted iso- to
hyperintense mass lesions with varying degrees of contrast enhance-
ment (CE).5,11-14 Oligodendrogliomas are reported to contact the brain
surface more commonly, whereas astrocytomas have been associated
with more peritumoral edema, lack of ventricular distortion, and iso-
to hyperintense T1-weighted signal.13,14 Tumors with mild to no CE,
absent cystic structures, and tumor location other than the thalamo-
capsular region have been associated with low-grade gliomas.14 Grade
and type of histologically confirmed intracranial gliomas in dogs using
these MRI features found an accuracy of 53.3% and 60% for
predicted tumor grade and type, respectively.15
Standard veterinary practice in recent years has been to use the
2007 World Health Organization (WHO) human glioma classification to
grade canine gliomas.16,17 This classified and graded human tumors based
on analysis of clinical outcome and survival relative to specific pathologic
criteria. However, little is known about whether histologic tumor type
and grade correlates with biologic behavior in canine gliomas. To date,
information on tumor progression and outcome after treatment is anec-
dotal.18 Since 2007, advances in molecular genetics and biology have
enhanced our understanding and subclassification of human gliomas,
which led in 2016 to an updated edition of the WHO brain tumor classifi-
cation.19 Subsequently, the Comparative Brain Tumor Consortium (CBTC)
of the National Cancer Institute proposed a revised diagnostic classifica-
tion of canine gliomas.8 Their aim was to provide an updated canine-
specific scheme for clinical and molecular data to be added into a mor-
phologic diagnosis, to assist with prediction of tumor behavior.
The aims of this study were to enhance this revised diagnostic
classification by further characterizing the epidemiologic, clinicopath-
ologic, diagnostic imaging, and outcome features of gliomas in dogs in
a large sample. We assess the relationship between these features
and tumor histological type and grade, based on the new diagnostic
classification for dogs.
2 | MATERIALS AND METHODS
This study was approved by the Research Ethics Committee of the
School of Veterinary Medicine of the University of Glasgow
(Ref33a/17). The clinical records of dogs presented to 7 European
referral centers between 2005 and 2018 were retrospectively ana-
lyzed. Dogs were included if they had a histopathologic diagnosis of
glioma. Samples were obtained by means of surgical biopsy or at nec-
ropsy within 24 hours from death.
2.1 | Morphologic diagnosis
All samples were fixed in 10% neutral buffered formalin. Fixation times
varied because of the multicentric and retrospective nature of the study;
2 JOSE-LÓPEZ ET AL.
however, this was always <5 days. After fixation, transverse sections of
the brain or spinal cord were made and samples including the tumor area
were routinely processed. Morphologic evaluation was performed on
4 μm paraffin-embedded sections stained with hematoxylin and eosin.
All gliomas were reviewed and classified by a board-certified patholo-
gist (M. Pumarola) using the CBTC diagnostic scheme.8 When available,
samples were further evaluated by immunohistochemistry for glial fibrillary
acidic protein (GFAP) (Z0334; Dako; Glostrup; Denmark; 30-minute incu-
bation at a dilution of 1:500), and Olig2 protein (AB 9610; Merck Mil-
lipore; Darmstadt; Germany; 30-minute incubation at a dilution of 1:100).
For both markers, slides were scored on a scale of 0 to 4 as previously
described.20 Immunohistochemical characterization of 16 cases (dogs
10-20, 76-80; Supplementary Table 1) was reported previously.20-22
Histopathology reports and available tissue were reviewed for fea-
tures of infiltrative spread consisting of invasion of adjacent central ner-
vous system (CNS) regions as well as presence of secondary structures of
Scherer, including perineuronal and perivascular satellitosis, subpial and
subependymal tumor cell condensation, and invasion along white matter
tracts.8,17,19,23 Extension through the corpus callosum into the contralat-
eral hemisphere was documented as butterfly glioma.19,24 Gliomatosis cer-
ebri growth pattern was recorded as recently defined.19,25
Evidence of extension into the subarachnoid space (tumor spread
through the pia mater with or without proliferation within the lep-
tomeninges), ventricular invasion or drop metastases was noted.26-29
Penetration of the bone21 or infiltration of other non-CNS structures
were also recorded. Finally, postmortem examination reports were
reviewed for the presence of metastases elsewhere in the body.5
2.2 | Anatomic location of tumors
Gliomas were allocated into 1 of 4 main anatomic locations: hemi-
spheric (cerebral hemispheres including deep gray matter), diencepha-
lon, infratentorial, and spinal cord. Within these regions, the specific
location of the largest portion of the tumor was recorded as fronto-
olfactory, parietal lobe (including the adjacent corpus callosum),
temporal lobe (including the piriform lobe), occipital lobe, ventricles,
diencephalon, cerebellum, brainstem, and spinal cord segment
corresponding with the overlying vertebrae.8,14,30 Furthermore, any
degree of involvement of the diencephalon was noted.5,13
2.3 | Dog demographics, clinicopathologic data,
and staging
Demographic data (age, sex, and breed), presenting clinical signs, and
physical and neurologic examination findings were recorded for each
case. Clinical signs were annotated as summarized on Table 1.
Cerebrospinal fluid (CSF) analysis results, when available before
treatment, were noted.
Reports of cases that underwent diagnostic imaging of the thorax,
abdomen, or both for staging were reviewed for the presence of
metastases.5
2.4 | Magnetic resonance imaging
Magnetic resonance imaging studies were performed with scanners of
variable field strength (0.2-1.5 T). All studies included T2-weighted
sagittal and transverse sequences and both, precontrast and post-
contrast (gadopentate dimeglumine; Magnevist, Bayer Schering
Pharma AG, Berlin, Germany) T1-weighted transverse sequences.
When available, additional fluid-attenuation inversion recovery
(FLAIR) dorsal or transverse sequences, gradient-recalled echo (GRE)
transverse sequences, T2-weighted dorsal views, and precontrast and
postcontrast T1-weighted dorsal and sagittal views were evaluated.
Magnetic resonance imaging features were independently evalu-
ated by 2 board-certified neurologists (R. Gutierrez-Quintana, R. José-
Lopez) and classified based on the consensus opinion. Both observers
were aware that lesions were gliomas but were blinded to the histo-
pathologic type and grade and provided with standardized grading
instructions. The MRIs were classified on the basis of 20 criteria
adapted from a recent study.14 For each criterion, observers chose
1 option from those specified in Table 2. Spinal cord located gliomas
were excluded from the analysis.
Observers were provided with specific instructions for some MRI
criteria. If the tumor margins were clear, they were divided into
smooth and irregular whereas if they were indistinct, they were con-
sidered poorly defined. Each glioma was classified on the basis of sig-
nal intensity relative to cortical gray matter and signal uniformity on
T1-weighted, T2-weighted, and FLAIR images. Interpretation was
based on the majority of the tumor area. Similarly, on T1-weighted
postcontrast images, degree of CE was evaluated and classified based
on the pattern of the largest portion of the tumor. Peritumoral edema
was graded and cystic structures noted according to a previous
study.31 Subarachnoid CSF signal loss, midline shift, ventricular distor-
tion, brain herniations, and syringohydromyelia were all categorized
TABLE 1 Summary of clinical signs annotation
Clinical
finding
Descriptions used in this study (total number of
cases for each criterion)
Seizures None (35); isolated (32); cluster seizures (24)
Mentation Normal (28); lethargy/disorientation (14);
depression (48)
Behavior Normal (44); behavioral abnormalities (46)
Posture Normal (69); head tilt (11); head turn (2); low-head
carriage (6); kyphosis (1)
Gait Normal (37); ataxia, paresis, or both (53)
Proprioception Normal (23); deficits (67)




Normal (81); deficits (9)
Brainstem
signs
Yes (facial asymmetry (3); abnormal eye
movements/position (10); anisocoria (3);
pupillary light reflex deficits (3)); no (75)
Hyperesthesia Yes (14); no (76)
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independently and subsequently considered for mass effect
grading.14,32
Additionally, brain MRIs were evaluated for features of tumor
spread, categorized as specified in Table 2. For spread from the ana-
tomic location containing the largest fraction of the tumor to neighbor-
ing brain structures or distant foci, observers were instructed to provide
a freehand description of the anatomic region/s tumors were extending
to. Tumor growth patterns consistent with butterfly glioma or
gliomatosis cerebri were recorded.19,24,25 Leptomeningeal CE with asso-
ciated FLAIR hyperintensity within the sulci was recorded as well.25,26
When present, this was also annotated as extension into the subarach-
noid space as was tumor invasion of the subarachnoid space without
associated meningeal MRI changes. Spread along the CSF pathways
including ventricular invasion and drop metastases was noted too.26-29
Similarly, propagation to non-CNS structures was recorded.
Finally, based on the observations of published MRI predictors
of canine glioma type and grade (summarized in Supplementary
Table 2), investigators predicted the grade (high or low) and type
(astrocytoma or oligodendroglioma) for each tumor.13-15 Accuracy
for predicting the lesion grade and type on MRI compared to histo-
pathologic diagnosis was performed using the consensus opinion of
both observers.
2.5 | Treatment and outcome
Treatment groups were defined as definitive if specific treatment
modalities including surgical resection, radiotherapy, or chemotherapy
were used in any combination, and palliative if corticosteroid, anti-
epileptic, or analgesic medications were the only therapeutic
TABLE 2 Standardized MRI interpretation criteria for intracranial gliomas included in this study (n = 74)
MRI criteria Descriptions used in this study (total number of cases for each criterion)
Origin Intra-axial (72); extra-axial (2)
Margins Poorly defined (25); smooth (44); irregular (5)
Shape Spherical or ovoid/elongate (47); amorphous (24); lobulated (3)
Signal
T2-intensity Hypointense (3); isointense (0); hyperintense (71)
T2-uniformity Homogeneous (22); heterogeneous (52)
T1-intensity Hypointense (60); isointense (14); hyperintense (0)
T1-uniformity Homogeneous (15); heterogeneous (59)
FLAIR intensity Hypointense (11); isointense (0); hyperintense (63)
FLAIR uniformity Homogeneous (16); heterogeneous (58)
GRE signal voidsa None (25); single (6); multiple (6); diffuse (majority of tumor) (4)
Degree of CE None (19); mild (20); moderate (19); severe (16)
CE pattern None (19); focal (1); nonuniform (28); uniform (entire tumor) (8); partial ring (7); complete ring (11)
Cystic structures None (44); cyst (16); ITFs (14)
Peritumoral edema None (7); peritumoral (≤10 mm beyond tumor margins) (47); extensive (>10 mm beyond tumor margins) (20)
Mass effect None (3); mild (16); moderate (29); severe (26)
Subarachnoid CSF signal loss Yes (63); no (11)
Midline shift Yes (54); no (20)
Ventricular distortion Yes (68); no (6)
Brain herniationsb None (31); subfalcine (2); transtentorial (24); foramen magnum (19)
Syringohydromyelia Yes (24); no (50)
Spread
Adjacent brain structures None (22); butterfly glioma (3); gliomatosis cerebri growth pattern (5); freehand description (44)
Brain surface contact Yes (56); no (18)
Leptomeningeal CE Yes (25); no (49)
Ventricular contact Yes (62); no (12)
CSF pathwaysb None (26); subarachnoid space (25); ventricular invasion (33); drop metastases (8)
Other structuresb None (60); penetration of bone (9); other (freehand description) (6)
Abbreviations: CE, contrast enhancement; CSF, cerebrospinal fluid; FLAIR, fluid-attenuation inversion recovery; GRE, gradient-recalled echo; ITFs,
intratumoral accumulations of fluid; MRI, magnetic resonance imaging; T1, T1-weighted; T2, T2-weighted.
aGRE images were only obtained in 41 gliomas.
bMore than 1 criterion could be observed for a single case.
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interventions.33 Survival was defined for all cases from time of MRI
diagnosis, and only for cases with survival times >1 day to exclude
animals euthanized at the time of diagnosis.33
2.6 | Statistical analyses
All analyses were carried out using SAS 9.4 (SAS Institute Inc,
Cary, North Carolina) and R 4.0.2 (R Foundation for Statistical
Computing, Vienna, Austria). When not specified, alpha level for
determination of significance was .05 and trends were discussed
for alpha .1.
Interobserver agreement for each MRI criterion was assessed
using Cohen's kappa. Values of 0.81-1.00 were considered to indicate
excellent agreement; 0.61-0.80, good agreement; 0.41-0.60, moder-
ate agreement; 0.21-0.40, fair agreement; 0.01-0.20, poor agreement,
and 0.00, chance agreement.
Agreement between histopathologic diagnosis (reference test) of
type and grade and classification of glioma type and grade following
previously published MRI criteria13,14 was analyzed using specificity
and sensitivity for detection of astrocytoma for type and high for
grade.
Associations between tumor location, patient demographics, clini-
cal signs, MRI criteria, and tumor type and grade were performed in
2 stages, first univariate analysis, and then multivariable analysis. Uni-
variate analysis was done using contingency tables and Fisher's exact
test. Variables with P value <.25 were used for the multivariable
model. For multivariable analysis, forward stepwise logistic regression
was used. A P-value to enter the model of <.20 and to remain of <.05
was used. Final logistic regression model fit was evaluated using the
Hosmer-Lemeshow goodness-of-fit test.
Associations between all risk factors and hazard of death was per-
formed for dogs with survival of >1 day and available MRI for revision
using univariable followed by multivariable Cox proportional hazard
modeling. All risk factors with a P value <.25 in the univariate analysis
were used in the multivariable analysis. A forward stepwise manual
approach was used to build the multivariable model. Risk factors were
kept in the final model after assessing for confounding with a P value
of .05. The proportional hazards assumption was tested by visual
inspection of log-minus-log survival plots and statistical assessment of
residuals.
3 | RESULTS
3.1 | Morphologic diagnosis
Ninety-one dogs with histopathological diagnosis of glioma were
identified. Ten cases were identified by surgical biopsy and 81 cases
were diagnosed at necropsy. Of these, 68.1% were classified as
oligodendroglioma (52 high-grade and 10 low-grade), 18.7% as astro-
cytoma (16 high-grade and 1 low-grade), and 13.2% as undefined
glioma (12, all high-grade).
Immunohistochemistry results for GFAP were available for
60 cases with a mean immunoreactivity score of 0.32/4 (range, 0-2/4)
on 35 oligodendrogliomas, 1.71/4 (range, 0-4/4) on 14 astrocytomas,
and 1.55/4 (range, 0-4/4) on 11 high-grade undefined gliomas (HUs).
Olig2 immunoreactivity results were available for 57 cases with mean
scores of 2.67/4 (range, 1-4/4) on 36 oligodendrogliomas, 1.85/4
(range, 0-4/4) on 13 astrocytomas, and 2/4 (range, 1-3/4) on 8 HUs.
Information on histopathologically confirmed infiltrative spread
was available for 75 cases. Invasion of neighboring brain structures
was observed in 51/75 cases including 35 oligodendrogliomas
(32 high-grade and 3 low-grade), 10 high-grade astrocytomas (HAs),
and 6 HUs. Secondary structures of Scherer were noted in 28/75
cases: 19 oligodendrogliomas (18 high-grade and 1 low-grade), 6 HAs,
and 3 HUs. These consisted of perivascular satellitosis and subpial
tumor cell condensation (9 cases, respectively), and perineuronal
satellitosis, subependymal tumor cell condensation, and white matter
tract invasion (7 cases, respectively) in any combination. Three high-
grade oligodendrogliomas (HOs) presented as butterfly gliomas
(Figure 1A-C) whereas gliomatosis cerebri growth pattern was seen in
3 HAs and 1 HU.
Ventricular invasion was confirmed in 24/75 cases (18 HOs,
4 HAs, 1 HU, and the only low-grade astrocytoma [LA]). Subarachnoid
spread with or without proliferation within the leptomeninges was
noted in 22/75 gliomas (16 HOs, 4 HAs, and 2 HUs). Drop metastases
were found in 9 HOs and 1 HA. Additionally, 1 HA presented 2 inde-
pendent foci (Figure 1D-G).
Information on spread to non-CNS structures and extraneural
metastases was available in 50 cases. Penetration of the cribriform
plate and infiltration of the ethmoturbinates and nasal mucosa was
confirmed in 3 HOs whereas osteolytic calvarial invasion was
noted on a previously reported HA.21 Pituitary gland infiltration
(Figure 1H-J) was found in 1 of each of HA, HO, and low-grade
oligodendroglioma (LO). No metastases were found elsewhere in
the body.
3.2 | Location of gliomas within the CNS
There were 69/91 (76%) hemispheric gliomas, 14/91 (15%) dience-
phalic, 5/91 (6%) infratentorial, and 3/91 (3%) in the spinal cord.
Geographic distribution within the brain of type and grade of glioma
is summarized in Figure 2A. Within the cerebral hemispheres
(Figure 2B), 29/69 tumors (42%) had a fronto-olfactory location,
25/69 (36%) were in the temporal lobe, 11/69 (16%) in the parietal
lobe, and 4/69 (6%) were primarily intraventricular. All of the latter
were located within the lateral ventricles and consisted of HOs. In
addition to the 14 primarily diencephalic gliomas, another 16 gliomas
involved the diencephalon to some extent (diencephalic involve-
ment by tumor type and grade is presented in Table 3). Infratentorial
gliomas included 4 HAs (brainstem, 3; cerebellum, 1) and 1 HO
(brainstem). Spinal cord gliomas consisted of 2 HOs located at the
level of C1 and T11 vertebrae, respectively, and 1 LO extending
from C7 to T5 vertebral bodies.
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3.3 | Demographics, clinicopathologic features,
and staging
Median age of dogs at diagnosis of glioma was 7.9 years (range,
1.5-13.0 years). There were 40/91 (44%) intact males, 11/91 (12%)
castrated males, 21/91 (23%) intact females, and 19/91 (21%) spayed
females. The ratio for all males/females was 1.28, and 1.9 for intact
males/females. Seventy-eight percent of the cases (71/91) belonged
to brachycephalic dog breeds including 40/91 (44%) Boxers, 26/91
(29%) Bulldogs (French, 23; English, 1; and not otherwise specified, 2),
F IGURE 1 Transverse (A) and dorsal (B) T1-weighted postcontrast magnetic resonance (MR) images of a ring-enhancing high-grade
oligodendroglioma (HO) showing the typical features of butterfly glioma with extensive involvement of the corpus callosum leading to bihemispheric
spread. Photomicrograph of the same HO as in (A) and (B) occupying the lumen of the lateral ventricle and infiltrating the cingulate gyrus (top of the
figure) and the corpus callosum (bottom of the figure) (C). The inset shows neoplastic cells invading the corpus callosum towards the contralateral
ventricle (the oval represents an area of higher neoplastic cell density). HE stain. Scale bar = 1 mm (inset 200 μm). Transverse fluid-attenuation
inversion recovery MR image at the level of the tentorium cerebelli demonstrating 2 heterogeneously hyperintense independent foci of a high-grade
astrocytoma (D). Dorsal T2-weighted images obtained at the level of the red (E) and the yellow (F) dotted lines show the largest tumor in the
cerebellum and a second focus in the right occipital lobe, respectively. Both foci were characterized by large sized anisokaryotic cell populations with
scant cytoplasm growing in a solid pattern (G). A mitotic figure is present (arrow) as well as glomeruloid-like vessels (arrowheads). HE stain. Scale
bar = 50 μm. Midsagittal T2-weighted images of a poorly defined, heterogeneously hyperintense HO extending from the fronto-olfactory area to the
diencephalon (H). Note the enlarged and hyperintense pituitary gland (arrow). Severe nonuniform enhancement of the pituitary gland was noted on
T1-weighted postcontrast images whereas this was mild for the intra-axial tumor. Dorsal view of the unfixed base of the neurocranium in the same
dog as (H) demonstrating an expanded pituitary gland (asterisk) (I). Photomicrograph of the pituitary gland of the dog in (H) and (I) revealing severe
infiltration of the hypophyseal lobules by the neoplastic cell population (J). HE stain. Scale bar = 500 μm
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3/91 (3%) Dogues de Bordeaux, and 2/91 (2%) Staffordshire Bull Ter-
riers. The breeds of the remaining 22% of dogs are captured on Sup-
plementary Table 1.
Time between onset of clinical signs and presentation ranged
between <1 and 180 days (median 14 days) for all gliomas. The main
presenting complaint in 62% (56/91) of the cases was seizures either
isolated (32 dogs) or in clusters (24). Of these, 5/56 (9%) presented
with a normal interictal neurologic examination and seizures as the
only clinical sign. In addition to seizures, the most common presenting
neurologic signs included proprioceptive deficits (67/90 cases, 74%),
mentation changes (62/90 cases, 69%), gait abnormalities (53/90
cases, 59%), visual deficits (49/90 cases, 54%), and behavioral changes
(46/90 cases, 51%). The remaining clinical signs are outlined in
Table 1 and most common neurologic signs by tumor type and grade
are presented in Table 3.
Cerebrospinal fluid was collected in 23 dogs. The results are sum-
marized in Table 4. These were within reference limits in 31.6%
(6/19), consistent with albuminocytologic dissociation in 36.8% (7/19)
and with an elevated total nucleated cell count in 34.8% (8/23) cases.
Mixed cell pleocytosis was the most common cytologic abnormality.
No neoplastic cells were detected. Thoracic radiographs (40 cases)
and CT (8), as well as abdominal ultrasonography (40 cases) or CT (3),
failed to reveal abnormalities suggestive of metastatic disease.
3.4 | Magnetic resonance imaging
Magnetic resonance imaging was obtained for diagnosis in 87 dogs. The
remaining 4 dogs were euthanized on presentation at their owners
request in view of the clinical suspicion and severity of clinical signs.
The MRI studies of 77 cases were available for review, including 74 brain
and 3 spinal cord gliomas. Median time between MRI and postmortem
examination was 1 day (range, <1-1104 days). All brain studies included
FLAIR sequences whereas GRE images were attained on 41.
Magnetic resonance imaging features of spinal cord gliomas con-
sisted of T2-weighted hyperintense, T1-weighted isointense focal, or
diffuse mass lesions with none to severe CE located intramedullary
except for the HO at C1 that appeared intradural extramedullary
(Figures 3A-C).
The MRI features of intracranial gliomas are captured in Table 2.
All intracranial gliomas in this study were intra-axial except for a HA
(Figures 3D-F) and a previously reported case of leptomeningeal
oligodendrogliomatosis reclassified as HO.22 Spread to adjacent brain
structures was detected in 52/74 (70%) gliomas and further charac-
terized as butterfly glioma in 3 HOs and as gliomatosis cerebri growth
pattern in 4 HAs and 1 HU. Extension outside the CNS including pen-
etration into the bone and invasion of the pituitary gland was
suspected in 9/74 and 6/74 gliomas, respectively. The MRI findings
by tumor type and grade are presented in Table 5.
Supplementary Figure 1 shows the interobserver agreement for
all the MRI variables studied. Kappa values were excellent or good in
most cases except for predicted tumor grade and spread to bone
structures that showed moderate agreement, and poor for predicted
tumor type.
Evaluation of previously published criteria13,14 for prediction of
intracranial glioma type and grade demonstrated a sensitivity
of 58.8% (95% confidence interval [CI], 35.4%-82.2%) and specificity
of 68.8% (95% CI, 55.6%-81.8%) for the diagnosis of astrocytoma,
and a sensitivity of 67.2% (95% CI, 55.2%-79.3%) and specificity
57.1% (95% CI, 20.5%-93.8%) for the diagnosis of high-grade.
3.5 | Associations among tumor location,
demographics, clinical signs, MRI features, and glioma
type and grade
The preliminary univariate analysis (Tables 3 and 5) showed associa-
tions between glioma type and presence of facial or nasal sensation
F IGURE 2 Anatomic distribution of intracranial gliomas in 88 dogs classified according to the Comparative Brain Tumor Consortium
diagnostic scheme (A). Specific location of 65 hemispheric gliomas (B). Note there were an additional 4 high-grade oligodendrogliomas primarily
located within the lateral ventricles
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TABLE 3 Univariate analysis of tumor location, patient demographics, and clinical features of 91 gliomas based on type and grade. Table











(n = 11) P value
Location
Diencephalon 11.8 (2) 14.5 (9) 25.0 (3) .07 13.8 (11) 27.3 (3) .28
Hemispheric 64.7 (11) 79.0 (49) 75.0 (9) 77.5 (62) 63.6 (7)
Infratentorial 23.5 (4) 1.6 (1) 0 (0) 6.3 (5) 0 (0)
Spinal cord 0 (0) 4.9 (3) 0 (0) 2.5 (2) 9.1 (1)
Diencephalic involvement 29.4 (5) 33.9 (21) 33.3 (4) .99 33.8 (27) 27.3 (3) .99
Demographics
Age (>96 months) 53.0 (9) 46.8 (29) 58.3 (7) .73 50.0 (37) 45.5 (4) .78
Sex
F 11.8 (2) 25.8 (16) 25.0 (3) .86 26.3 (21) 0 (0) .06
FN 29.4 (5) 19.4 (12) 16.7 (2) 20.0 (16) 27.3 (3)
M 41.2 (7) 43.6 (27) 50.0 (6) 40.0 (32) 72.7 (8)
MN 17.7 (3) 11.3 (7) 8.33 (1) 13.8 (11) 0 (0)
Boxer breed 41.2 (7) 46.8 (29) 33.3 (4) .66 43.8 (35) 45.5 (5) .99
Bulldog breed 35.3 (6) 25.8 (16) 33.3 (4) .68 31.3 (25) 9.1 (1) .17
Boxer's phylogenetic clade34 82.4 (14) 79.0 (49) 66.7 (8) .64 78.7 (63) 72.7 (8) .7
Clinical features
Duration of signs (>3 days) 86.7 (15) 81.4 (50) 81.8 (10) .99 79.7 (64) 100.0 (11) .2
Seizures
None 41.2 (7) 37.1 (23) 41.7 (5) .87 38.8 (31) 36.4 (4) .99
Isolated 29.4 (5) 38.7 (24) 25.0 (3) 35.0 (28) 36.4 (4)
Cluster seizures 29.4 (5) 24.2 (15) 33.3 (4) 26.3 (21) 27.3 (3)
Mentation
Normal 11.8 (2) 36.1 (22) 33.3 (4) .21 27.9 (22) 54.6 (6) .08
Lethargy/disorientation 11.8 (2) 14.8 (9) 25.0 (3) 15.2 (12) 18.2 (2)
Depression 76.5 (13) 49.2 (30) 41.7 (5) 57.0 (45) 27.3 (3)
Behavioral abnormalities 58.8 (10) 47.5 (29) 58.3 (7) .62 51.9 (41) 45.5 (5) .76
Kyphosis/low-head carriage 5.9 (1) 8.2 (5) 8.3 (1) .99 7.6 (6) 9.1 (1) .99
Head tilt or turn 29.4 (5) 11.5 (7) 8.3 (1) .21 16.5 (13) 0 (0) .36
Gait abnormalities 47.1 (8) 62.3 (39) 50.0 (6) .42 58.2 (47) 54.6 (6) .99
Proprioceptive deficits 70.6 (12) 70.5 (44) 91.7 (11) .36 74.7 (60) 63.6 (7) .48
Vision
Normal 64.7 (11) 44.3 (27) 25.0 (3) .29 43.0 (34) 63.6 (7) .27
Unilateral deficits 29.4 (5) 37.7 (23) 50.0 (6) 38.0 (30) 36.4 (4)
Bilateral deficits 5.9 (1) 18.0 (11) 25.0 (3) 19.0 (15) 0 (0)
Facial/nasal sensation deficits 11.8 (2) 4.9 (3) 33.3 (4) .01 10.1 (8) 9.1 (1) .99
Facial asymmetry 0 (0) 4.9 (3) 0 (0) .99 3.8 (3) 0 (0) .99
Abnormal eye movements/position 11.8 (2) 13.1 (8) 0 (0) .52 11.4 (9) 9.1 (1) .99
Anisocoria/PLR deficits 11.8 (2) 6.6 (4) 0 (0) .55 7.6 (6) 0 (0) .99
Hyperesthesia 17.7 (3) 14.8 (9) 16.7 (2) .91 17.7 (14) 0 (0) .2
Abbreviations: F, female; FN, female neutered; M, male; MN, male neutered; PLR, pupillary light reflex.
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range (cells/μL) Differential cytology
LO (3) 1 (2) 1 (3) 1 (2) 1 (2) 23.3 (20-26.5) 28 (1-81) Eosinophilic pleocytosis, 1e
HO (13) 8 (11) 3 (13) 6 (11) 3 (11) 143.0 (10.1-780) 38 (0-460) Increased percentage of
neutrophils (62%), 1f; Mixed
cell pleocytosis, 3g
HA (4) 3 (4) 3 (4) 0 (4) 1 (4) 206.1 (22.5-736) 15 (0-27) Mixed cell pleocytosis, 3
HU (3) 1 (2) 1 (3) 0 (2) 1 (2) 75.1 (20-130.2) 10 (0-27) Neutrophilic pleocytosis, 1h
Abbreviations: ACD, albuminocytologic dissociation; CSF, cerebrospinal fluid; HA, high-grade astrocytoma; HO, high-grade oligodendroglioma; HU, high-
grade undefined glioma; LO, low-grade oligodendroglioma; TNCC, total nucleated cell count; TP, total protein.
aNumber of cases in which CSF information was available.
bNumber of cases with >25 mg/dL TP concentration (number of cases with available information).
cNumber of cases with >5 cells/μL (number of cases with available information).
dNumber of cases with >25 mg/dL TP concentration and <5 cells/μL (number of cases with available information).
eDefined as CSF with >50% eosinophils.
fDefined as CSF >2% nondegenerated neutrophils.35
gDefined as CSF with a mixture of mostly lymphocytes and large mononuclear cells and >20% contribution of neutrophils and, occasionally, eosinophils.35
hDefined as CSF with >75% neutrophils.
F IGURE 3 Midsagittal (A) and transverse (B) T2-weighted magnetic resonance (MR) images of a heterogeneously hyperintense high-grade
oligodendroglioma at the level of C1 vertebra (arrow) identified as intradural-extramedullary by both observers. Note the mass extension into the
foramen magnum (arrowhead). Photomicrograph of the same tumor as (A) and (B) demonstrating a highly cellular proliferation in direct contact
with the thickened pia mater (arrow) in the dorsal aspect of the spinal cord (C). Note the severe hemorrhages ventrally where the mass is
compressing the spinal cord parenchyma (asterisk). HE stain. Scale bar = 500 μm. Transverse T1-weighted postcontrast MR image of an extra-
axial nonuniformly contrast-enhancing high-grade astrocytoma ventral to the mesencephalon (arrow) (D). Formalin-fixed transverse section of the
brain at the level of (D) demonstrating the extra-axial appearance of the tumor (arrow) (E). Photomicrograph of the paraffin-embedded tumor in
(D) and (E) showing a highly cellular proliferation spreading through the subarachnoid space ventral to the mesencephalon (asterisk) with multiple
foci of hemorrhage (arrowheads) and necrosis (arrow) (F). HE stain. Scale bar = 500 μm
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TABLE 5 Univariate analysis of MRI criteria of 74 intracranial gliomas based on type and grade. Table shows percentage of each criterion







(n = 8) P value High (n = 67) Low (n = 7) P value
Margins
Smooth 47.1 (8) 69.4 (34) 25.0 (2) .02 56.7 (38) 85.7 (6) .53
Irregular 11.8 (2) 2.0 (1) 25.0 (2) 7.5 (5) 0 (0)
Poorly defined 41.2 (7) 28.6 (14) 50.0 (4) 35.8 (24) 14.3 (1)
Shape
Amorphous 29.4 (5) 28.6 (14) 62.5 (5) .09 34.3 (23) 14.3 (1) .24
Lobulated 5.9 (1) 2.0 (1) 12.5 (1) 3.0 (2) 14.3 (1)
Spherical or ovoid/elongate 64.7 (11) 69.4 (34) 25.0 (2) 62.7 (42) 71.4 (5)
Signal
T2-hypointensitya 11.8 (2) 2.0 (1) 0 (0) .26 4.5 (3) 0 (0) .99
T2-homogeneity 29.4 (5) 32.7 (16) 12.5 (1) .63 28.4 (19) 42.9 (3) .42
T1-hypointensityb 47.1 (8) 95.9 (47) 62.5 (5) <.001 80.6 (54) 85.7 (6) .99
T1-homogeneity 29.4 (5) 14.3 (7) 37.5 (3) .15 19.4 (13) 28.6 (2) .62
FLAIR hypointensityc 11.8 (2) 16.3 (8) 12.5 (1) .99 14.9 (10) 14.3 (1) .99
FLAIR homogeneity 29.4 (5) 16.3 (8) 37.5 (3) .23 22.4 (15) 14.3 (1) .99
GRE signal voidsd 50.0 (5) 37.0 (10) 25.0 (1) .7 41.0 (16) 0 (0) .51
Contrast enhancement
Moderate to severee 58.8 (10) 44.9 (22) 37.5 (3) .56 49.3 (33) 28.6 (2) .43
CE pattern
No CE 17.7 (3) 27.5 (14) 25.0 (2) .42 22.1 (15) 50.0 (4) .37
Partial or complete ring 23.5 (4) 27.5 (14) 0 (0) 25.0 (17) 12.5 (1)
Other patterns 58.8 (10) 42.9 (21) 75.0 (6) 50.7 (34) 37.5 (3)
Tumor characteristics
Cystic structures 41.2 (7) 42.9 (21) 25.0 (2) .72 40.3 (27) 42.9 (3) .99
Peritumoral edema
None 5.9 (1) 12.2 (6) 0 (0) .28 9.0 (6) 14.3 (1) .84
Peritumoral 47.1 (8) 67.4 (33) 75.0 (6) 64.2 (43) 57.1 (4)
Extensive 47.1 (8) 20.4 (10) 25.0 (2) 26.9 (18) 28.6 (2)
Mass effect
None 11.8 (2) 2.0 (1) 0 (0) .11 4.5 (3) 0 (0) .11
Mild 17.7 (3) 26.5 (13) 0 (0) 20.9 (14) 28.6 (2)
Moderate 23.5 (4) 44.9 (22) 37.5 (3) 35.8 (24) 71.4 (5)
Severe 47.1 (8) 26.5 (13) 62.5 (5) 38.8 (26) 0 (0)
Subarachnoid CSF
signal loss
88.2 (15) 81.6 (40) 100.0 (8) .62 85.1 (57) 85.7 (6) .99
Midline shift 64.7 (11) 73.5 (36) 87.5 (7) .52 71.6 (48) 85.7 (6) .66
Ventricular distortion 88.2 (15) 91.8 (45) 100.0 (8) .82 91.0 (61) 100.0 (7) .99
Brain herniations
None 35.3 (6) 44.9 (22) 37.5 (3) .09 41.8 (28) 42.8 (3) .21
Transtentorial or subfalcine 41.2 (7) 34.7 (17) 0 (0) 29.9 (20) 57.1 (4)
Foramen magnum 23.5 (4) 20.4 (10) 62.5 (5) 28.4 (19) 0 (0)
SHM 35.3 (6) 30.6 (15) 37.5 (3) .8 35.8 (24) 0 (0) .09
Spread
Adjacent brain structures 58.8 (10) 69.4 (34) 100.0 (8) .09 74.6 (50) 28.6 (2) .02
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deficits (P = .01), tumor margins (P = .02) on MRI, T1-weighted signal
intensity (P < .001), and ventricular contact (P = .04).
Multivariable logistic regression analysis indicated that
oligodendrogliomas were more often associated with smooth margins
(Figure 4A) than astrocytomas (odds ratio [OR], 42.5; 95% CI, 2.42-
744.97; P = .04) or undefined gliomas (OR, 84; 95% CI, 3.43-999.99;
P = .02). Oligodendrogliomas were also associated with T1-weighted








(n = 8) P value High (n = 67) Low (n = 7) P value
Brain surface contact 76.5 (13) 77.6 (38) 62.5 (5) .65 74.6 (50) 85.7 (6) .99
Leptomeningeal CE 47.1 (8) 28.6 (14) 37.5 (3) .34 35.8 (24) 14.3 (1) .26
Ventricular contact 64.7 (11) 87.8 (43) 100.0 (8) .05 83.6 (56) 85.7 (6) .99
CSF pathways
Subarachnoid space 47.1 (8) 28.6 (14) 37.5 (3) .34 35.8 (24) 14.3 (1) .41
Ventricular invasion 23.5 (4) 49.0 (24) 62.5 (5) .09 46.3 (31) 28.6 (2) .45
Drop metastases 0 (0) 16.3 (8) 0 (0) .16 11.9 (8) 0 (0) .99
Other structures
Pituitary gland 5.9 (1) 8.2 (4) 12.5 (1) .82 7.5 (5) 14.3 (1) .46
Penetration of bone 17.7 (3) 12.2 (6) 0 (0) .56 13.4 (9) 0 (0) .59
Abbreviations: CE, contrast enhancement; CSF, cerebrospinal fluid; FLAIR, fluid-attenuation inversion recovery; GRE, gradient-recalled echo; MRI,
magnetic resonance imaging; SHM, syringohydromyelia; T1, T1-weighted; T2, T2-weighted.
aAs opposed to T2-weighted hyperintensity seen in 88.2% (15) astrocytomas, 98% (48) oligodendrogliomas, and all undefined gliomas; 95.5% (64) high-
grade gliomas and all low-grade gliomas.
bAs opposed to T1-weighted isointensity seen in 52.9% (9) astrocytomas, 4.1% (2) oligodendrogliomas, and 37.5% (3) undefined gliomas; 19.4% (13) high-
grade gliomas and 14.3% (1) low-grade gliomas.
cAs opposed to FLAIR hyperintensity seen in 88.2% (15) astrocytomas, 83.7% (41) oligodendrogliomas, and 87.5% (7) undefined gliomas; 85.1% (57) high-
grade gliomas and 85.7% (6) low-grade gliomas.
dPercentages and total number of cases with signal voids out of 41 gliomas where GRE images were obtained.
eAs opposed to none to mild CE seen in 41.2% (7) astrocytomas, 55.1% (27) oligodendrogliomas, and 62.5% (5) undefined gliomas; 50.7% (34) high-grade
gliomas and 71.4% (5) low-grade gliomas.
F IGURE 4 Transverse T2-weighted magnetic resonance (MR) image of a high-grade oligodendroglioma (HO) in the right frontal lobe (arrow)
with smooth margins and in close contact with the lateral ventricle (asterisk) (A). Transverse T1-weighted image of a hypointense to gray matter
HO in the right temporal lobe (arrow) (B). Dorsal T2-weighted MR image showing a high-grade undefined glioma extending from the frontal
(arrow) to the temporal lobe (arrowhead) (C). Involvement of the parietal lobe and hippocampus were also noted and gliomatosis cerebri growth
pattern was subsequently confirmed on histopathology
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95% CI, 5.78-333.33; P < .001) or undefined gliomas (OR, 32.3; 95%
CI, 2.51-500.00; P = .008). Finally, oligodendrogliomas were more
often in contact with the ventricles (Figure 4A) than astrocytomas
(OR, 7.47; 95% CI, 1.03-53.95; P = .049).
For tumor grade, the univariate analysis (Tables 3 and 5) showed
associations with spread to adjacent brain structures (P = .02).
The multivariable logistic regression analysis indicated that spread
to neighboring brain structures (Figure 4C) was more often associated
with high-grade gliomas (OR, 6.02; 95% CI, 1.06-34.48; P = .04).
3.6 | Treatment and outcome
Survival time was available for all 87 dogs undergoing MRI for diagno-
sis. Forty-two dogs survived <1 day (euthanized at diagnosis) and
were excluded from further analysis to remove cases without intent
to treat. Of the 45 dogs that survived >1 day, 22 received palliative
treatment (10 HOs, 6 HAs, 3 HUs, and 3 LOs), and 23 received defini-
tive treatment (11 HOs, 5 HUs, 3 HAs, 3 LOs, and 1 LA). Treatment
modalities and survival data are outlined in Supplementary Table 1.
F IGURE 5 Kaplan-Meier survival curve for definitively and
palliatively treated dogs with intracranial glioma that survived >1 day
(n = 45). Dogs receiving definitive treatment survived significantly
longer (P = .03) than did dogs with palliative treatment. Survival time
represents the time from diagnosis to death or euthanasia. Shadow
areas represent 95% confidence intervals
TABLE 6 Multivariable Cox
proportional hazard ratios for the survival
analysis of 36 dogs surviving >1 day after
imaging diagnosis and available MRI
study for evaluation
Clinical or MRI variable P value Hazard ratio 95% confidence interval
Seizures <.001 0.044 0.011-0.173
Marginsa
Irregular .001 31.69 4.23-237.28
Poorly defined .003 7.57 2.04-22.18
Drop metastases <.001 53.15 6.25-452.22
T2-heterogeneity .001 6.93 2.21-21.73
Abbreviations: MRI, magnetic resonance imaging; T2-heterogeneity, T2-weighted heterogeneity.
aReference category: smooth margins.
F IGURE 6 Transverse T2-weighted magnetic resonance (MR) image of a left temporal lobe high-grade oligodendroglioma (arrowheads) with
poorly defined margins and heterogeneously hyperintense signal extending to the parietal lobe and invading the adjacent lateral ventricle (A).
Transverse T1-weighted postcontrast image at the same level demonstrating moderate non-uniform contrast enhancement of the parietal portion
of the tumor (arrow) (B). Transverse T1-weighted postcontrast image of the same dog demonstrating a contrast-enhancing drop metastasis in the
right cerebellum (arrowhead), just dorsal to the lateral aperture of the fourth ventricle (C)
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Among the >1-day survivors, definitive treatments were associated
with significantly (P = .03) longer survival (median survival time
[MST], 84 days; 95% CI, 45-190) than palliative treatment (MST,
26 days; 95% CI, 11-54) (Figure 5).
Univariate survival analysis is presented in Supplementary Table 3.
The multivariable Cox proportional hazards model included seizures
(hazards ratio [HR] 95% CI, 0.01-0.17) as a lower risk factor, and irreg-
ular (HR 95% CI, 4.2-237.3) or poorly defined (HR 95% CI, 2.0-22.2)
margins, T2-weighted heterogeneous signal (HR 95% CI, 2.21-21.7),
and drop metastases (HR 95% CI, 6.3-452.2) as risk factors for shorter
survival (Table 6; Figure 6). No confounding risk factors or interactions
were found and no evidence of violation of the proportional hazard
assumption was found.
4 | DISCUSSION
Our study provides predictive information for the clinical diagnosis of
glioma type and grade as well as their prognostic outcome for
affected dogs. New MRI characteristics for differentiation of glioma
type and grade are identified, and clinical and imaging findings are
associated with survival. Additionally, we describe previously
unreported features of these CNS tumors.
Glioma type and grade relative frequency in this study is consis-
tent with data from prior literature, indicating that oligodendroglial
and high-grade tumors are the most prevalent in dogs.3,8,36 We found
no associations between glioma location and tumor type or grade;
however, consistent with recent studies,8,13 our data suggest that gli-
omas in dogs, like their human counterparts,30 arise mainly in the
fronto-olfactory, temporal, and parietal regions of the cerebral hemi-
spheres. The reported increased likelihood of histologic involvement
of the diencephalon in astrocytomas in dogs was not observed in our
cohort.5,13 All gliomas in dogs reported to be primarily intraventricular
to date have been HOs.8,26,37
Almost 80% of the gliomas included herein occurred in brachyce-
phalic dog breeds belonging to the same phylogenetic clade,34
supporting glioma pronounced predilection for these breeds.3,5,8-10,13
However, contrasting other reports,8 the Boxers and Bulldogs in our
study did not show a higher prevalence of oligodendroglioma,
although this might have been related to smaller case numbers in our
sample. No associations were found between sex and tumor type or
grade, but the recently reported male sex predilection8 was confirmed
by our data and resembles the situation in humans.30
The most common signs of neurologic dysfunction in this series
included proprioceptive deficits, mentation changes, and seizures.
Over 60% of the cases were diagnosed after an inaugural seizure,
resembling previous studies in dogs4,5,38 and mirroring the situation in
humans.17,39 While no presenting clinical sign was associated with gli-
oma type or grade, seizures at onset was identified as a favorable
prognostic factor for duration of survival in both low- and high-grade
gliomas. Like in human gliomas, new-onset seizures might represent
an early warning sign for the presence of a brain tumor as other more
subtle signs of neurologic disease in dogs might go unnoticed by their
owners.39 Definitive treatment modalities contribute to seizure con-
trol in human patients and this could have influenced the improved
survival of these cases in our study; however, there were no associa-
tions between seizures at onset and treatment modality.
Although definitive diagnosis of glioma requires histopathologic
analysis of tumor tissue, biopsy or resection of tumors is not always
possible. Therefore, the ability to predict intracranial glioma type and
grade based on MRI characteristics has recently been investigated in
dogs.13-15 However, currently published MRI findings for predicting
grade and tumor type have proven inaccurate.15 We further analyzed
those MRI predictors in our larger sample and confirmed their low
sensitivity and specificity. Additionally, the low agreement for
predicted tumor type and grade using those features indicated high
interobserver variability. These might have been related to the overlap
of evaluated MRI features between tumor types and grades in our
population and the high variability of described predictors within each
tumor.
We assessed 74 brain MRI studies for additional indicators of gli-
oma type and grade and found that oligodendrogliomas were associ-
ated with smooth margins and T1-weighted hypointensity compared
to astrocytomas and undefined gliomas as well as more commonly in
contact with the ventricles than astrocytomas. Tumor spread to
neighboring brain structures was the only finding associated with
high-grade diagnosis. These are in contrast with reported associations
among peritumoral edema and astrocytomas, brain surface contact
and oligodendrogliomas, and CE and cystic structures with tumor
grade.13,14 Conversely to previous reports,13,14 ventricular contact
alone, independent of distortion, was more common in
oligodendrogliomas than astrocytomas. The only similarity between
this and prior studies was the significantly low likelihood of
T1-weighted hypointensity in astrocytomas,14 which was shared by
undefined gliomas in this series. Although we used comparable meth-
odology to a previous report,14 differing results might stem from
inclusion of undefined gliomas in our series and the potentially magni-
fied significance of individual outliers not representative of the gen-
eral population in that study,14 where statistics were performed using
155 MRI observations from 5 investigators in 31 gliomas, instead of
the consensus opinion used herein.
Interobserver agreement for individual MRI features associated
with glioma type and grade in our study was good to excellent; how-
ever, despite reported 89% sensitivity for MRI diagnosis of neoplastic
brain disease and 93.7% specificity and 84.4% sensitivity for diagnosis
of glioma in dogs, other differential diagnoses with overlapping imag-
ing characteristics still need to be considered.12,40
Differently from our observations, CE on MRI and in particular,
ring-enhancement, is usually associated with higher grade human glio-
mas.41-43 However, human LAs and approximately 50% of LOs can
show CE44-47 and its absence does not exclude high-grade gli-
oma.44,48,49 On the other hand, human oligodendrogliomas are usually
well demarcated and largely T1-hypointense,50,51 and glioblastomas
might extend widely to adjacent brain structures,52 resembling our
observations on canine oligodendrogliomas and high-grade gliomas,
respectively.
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Novel features of gliomas in dogs encountered in this study
included histopathologically confirmed butterfly growth pattern in
3 HOs and pituitary gland infiltration in different glioma types.
Reported human and canine butterfly gliomas to date are HAs; how-
ever, our findings indicate that, as in gliomatosis cerebri, this repre-
sents a pattern of spread rather than a distinct nosologic entity.19,24,53
Extension of glioma to the pituitary gland had not been described in
dogs and has only been confirmed once in humans.54 Other infre-
quent features reported here include penetration into the bone and
multifocal distribution. Multifocality as a result of CSF drop metasta-
ses occurs in oligodendrogliomas in dogs26-28; however, truly multiple,
independent gliomas have only been described in 1 dog and are a rare
presentation in humans.55,56 Additionally, we confirmed CSF seeding
in a HA in 1 dog, a dissemination pathway exhibited by less than 2%
of human glioblastomas.53 Finally, extra-axial appearance of astrocy-
toma had only been reported in a dog,15 and is an infrequent observa-
tion in humans.57,58
Data regarding treatment and survival in dogs with histopatholog-
ically confirmed glioma is scarce and yet to be added to the new clas-
sification. The survival analysis presented here is the most complete
to date; however, it has limitations inherent to the low case numbers
and results should be interpreted accordingly. The multivariable analy-
sis of available clinical and MRI findings identified prognostic factors
affecting survival in intracranial gliomas in dogs for the first time. In
addition to the favorable association between new-onset seizures and
survival, a series of MRI features were identified as negative prognos-
tic indicators. Poorly defined and irregular tumor margins associated
death hazard was over 7 and 31 times as high as that associated with
smooth margins, respectively. Tumor T2-weighted heterogeneous sig-
nal and observation of drop metastases were also associated with
shorter survival. These prognostic factors differ from those reported
for human gliomas; nevertheless, prognosis in humans is currently
guided by isocitrate dehydrogenase mutation and 1p/19q status,19 for
which parallelisms have not been found in canine gliomas.59-63 Case
series with palliative treatment outcome information relating to gli-
oma type or grade are lacking. Canine studies evaluating experimental
therapies in >3 intracranial gliomas with detailed information on their
type and grade have reported MSTs of 119 days (n = 7),64 224 days
(n = 17),65 248 days (n = 8),66 and 257 days (n = 8).67 However, no
comparisons were made between differing types or grades. Similarly,
a recent study reported a MST of 66 days after surgical re-
section alone in 14 gliomas,68 8 of which were reclassified and
included in this study. Thus, we decided to further evaluate therapeu-
tic outcome in our larger sample of dogs surviving diagnosis. Despite
marked variability in treatment modalities (surgery, radiotherapy, che-
motherapy), MST for definitively treated cases (n = 23) was longer
(84 days) than for palliative treatment cases (n = 22; 26 days),
suggesting that definitive therapies provide a significant survival ben-
efit to dogs with intracranial gliomas, although this benefit appears to
be limited.
This series has some limitations intrinsic to its retrospective
nature and reflects the challenges inherent to the study of gliomas in
dogs, including variable MRI and treatment protocols, owner decisions
to euthanize rather than natural death, and erroneous or incomplete
record-keeping. Thus, the authors invite researchers to contribute to
the creation of a mutually accessible international multicenter data-
base to better enable evidence-based research in this field.
Additional limitations of the current study include the fact that
necropsy samples might not be representative of the original tumor
phenotype, which could change with tumor progression or be
influenced by treatments administered. Also, in cases where surgical
biopsies were obtained, these might have failed to reflect the overall
histologic features of the glioma sampled hampering accurate classifi-
cation. Finally, tumor typing and grading was established by a single
pathologist which could represent a potential source of bias in view of
the moderate agreement for glioma type and grade observed between
the multiple pathologists contributing to the CBTC classification.8
In conclusion, smooth margins, T1-weighted hypointensity and
ventricular contact on MRI diagnosed intracranial gliomas, could allow
differentiation between oligodendrogliomas and other glial tumor
types in dogs. High-grade glioma should be suspected if spread over
more than 1 brain region is observed. Definitive therapies appear to
improve survival time. New onset seizures are associated with a more
favorable prognosis, whereas MRI observed irregular or poorly
defined tumor margins, T2-weighted heterogeneity and drop metasta-
ses are negative prognostic indicators. No associations were found
between survival and tumor location or the CBTC morphologic
classification.8
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